These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3858802)

  • 21. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats.
    Carlsson M; Carlsson A; Eriksson E
    Eur J Pharmacol; 1987 Oct; 142(1):39-43. PubMed ID: 3691635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y; Fage D; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.
    Hjorth S; Svensson K; Carlsson A; Wikström H; Andersson B
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jul; 333(3):205-18. PubMed ID: 3762735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A
    Psychopharmacology (Berl); 1983; 81(2):89-99. PubMed ID: 6415751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O
    Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers.
    Eriksson E; Modigh K; Carlsson A; Wikström H
    Eur J Pharmacol; 1983 Dec; 96(1-2):29-36. PubMed ID: 6662196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
    Clark D; Salah RS; Galloway MP
    Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
    Bøgesø KP; Arnt J; Lundmark M; Sundell S
    J Med Chem; 1987 Jan; 30(1):142-50. PubMed ID: 3806591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the enantiomers of 3-PPP on DA1 and DA2 dopamine receptors in the dog.
    Kohli JD; Glock D; Goldberg LI
    Eur J Pharmacol; 1985 Aug; 114(3):305-10. PubMed ID: 4065203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation.
    Oberlander C; Boissier JR
    J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
    Liljefors T; Wikström H
    J Med Chem; 1986 Oct; 29(10):1896-904. PubMed ID: 3761309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.
    Clark D; Hjorth S; Carlsson A
    Eur J Pharmacol; 1984 Oct; 106(1):185-9. PubMed ID: 6099268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
    Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson AM; Thorberg SO; Nilsson JL; Svensson K; Hjorth S
    J Med Chem; 1984 Aug; 27(8):1030-6. PubMed ID: 6086923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A
    J Neural Transm Suppl; 1983; 19():153-61. PubMed ID: 6321646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.
    Mottola DM; Kilts JD; Lewis MM; Connery HS; Walker QD; Jones SR; Booth RG; Hyslop DK; Piercey M; Wightman RM; Lawler CP; Nichols DE; Mailman RB
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1166-78. PubMed ID: 12023552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.
    Rollema H; Feenstra MG; Grol CJ; Lewis MH; Staples L; Mailman RB
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Apr; 332(4):338-45. PubMed ID: 3736679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occurrence of yawning and decrease of prolactin levels via stimulation of dopamine D2-receptors after administration of SND 919 in rats.
    Matsumoto S; Yamada K; Nagashima M; Domae M; Shirakawa K; Furukawa T
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):21-5. PubMed ID: 2571944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
    Mulder TB; de Vries JB; Dijkstra D; Wiechers JW; Grol CJ; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):494-501. PubMed ID: 2830544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.